Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1303

1.

Combining naproxen and a dual amylin and calcitonin receptor agonist improves pain and structural outcomes in the collagen-induced arthritis rat model.

Katri A, Dąbrowska A, Löfvall H, Ding M, Karsdal MA, Andreassen KV, Thudium CS, Henriksen K.

Arthritis Res Ther. 2019 Feb 22;21(1):68. doi: 10.1186/s13075-019-1819-9.

2.

An amylin analogue attenuates alcohol-related behaviours in various animal models of alcohol use disorder.

Kalafateli AL, Vallöf D, Colombo G, Lorrai I, Maccioni P, Jerlhag E.

Neuropsychopharmacology. 2019 May;44(6):1093-1102. doi: 10.1038/s41386-019-0323-x. Epub 2019 Jan 23.

3.

Enhancement of oral bioavailability of salmon calcitonin through chitosan-modified, dual drug-loaded nanoparticles.

Liu L, Yang H, Lou Y, Wu JY, Miao J, Lu XY, Gao JQ.

Int J Pharm. 2019 Feb 25;557:170-177. doi: 10.1016/j.ijpharm.2018.12.053. Epub 2018 Dec 28.

PMID:
30597264
4.

An intestinal paracellular pathway biased toward positively-charged macromolecules.

Almansour K, Taverner A, Turner JR, Eggleston IM, Mrsny RJ.

J Control Release. 2018 Oct 28;288:111-125. doi: 10.1016/j.jconrel.2018.09.003. Epub 2018 Sep 6.

PMID:
30194947
5.

Inhibition of the fibrillation of highly amyloidogenic human calcitonin by cucurbit[7]uril with improved bioactivity.

Shang H, Zhou A, Jiang J, Liu Y, Xie J, Li S, Chen Y, Zhu X, Tan H, Li J.

Acta Biomater. 2018 Sep 15;78:178-188. doi: 10.1016/j.actbio.2018.07.045. Epub 2018 Aug 2.

PMID:
30076991
6.

Intra-articular delivery of a nanocomplex comprising salmon calcitonin, hyaluronic acid, and chitosan using an equine model of joint inflammation.

Sladek S, Kearney C, Crean D, Brama PAJ, Tajber L, Fawcett K, Labberte MC, Leggett B, Brayden DJ.

Drug Deliv Transl Res. 2018 Oct;8(5):1421-1435. doi: 10.1007/s13346-018-0557-x.

PMID:
29947020
7.

Salmon Calcitonin Attenuates Degenerative Changes in Cartilage and Subchondral Bone in Lumbar Facet Joint in an Experimental Rat Model.

Gou Y, Tian F, Kong Q, Chen T, Li H, Lv Q, Zhang L.

Med Sci Monit. 2018 May 7 [revised 2018 Jan 1];24:2849-2857. doi: 10.12659/MSM.910012.

8.

Synergistic and non-synergistic effects of salmon calcitonin and omega - 3 fatty acids on antioxidant, anti-inflammatory, and haematological indices in diabetic rats.

Adeyemi WJ, Olayaki LA.

Biomed Pharmacother. 2018 Mar;99:867-875. doi: 10.1016/j.biopha.2018.01.085. Epub 2018 Feb 20.

PMID:
29710486
9.

Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study.

Desai RJ, Sarpatwari A, Dejene S, Khan NF, Lii J, Rogers JR, Dutcher SK, Raofi S, Bohn J, Connolly J, Fischer MA, Kesselheim AS, Gagne JJ.

BMJ. 2018 Apr 3;361:k1180. doi: 10.1136/bmj.k1180.

11.

In Vitro-In Vivo Evaluation of an Oral Ghost Drug Delivery Device for the Delivery of Salmon Calcitonin.

Hibbins AR, Govender M, Indermun S, Kumar P, du Toit LC, Choonara YE, Pillay V.

J Pharm Sci. 2018 Jun;107(6):1605-1614. doi: 10.1016/j.xphs.2018.02.004. Epub 2018 Feb 13.

PMID:
29452142
12.

Activation of amylin receptors attenuates alcohol-mediated behaviours in rodents.

Kalafateli AL, Vallöf D, Jerlhag E.

Addict Biol. 2019 May;24(3):388-402. doi: 10.1111/adb.12603. Epub 2018 Feb 6.

13.

Three-Month Randomized Clinical Trial of Nasal Calcitonin in Adults with X-linked Hypophosphatemia.

Sullivan R, Abraham A, Simpson C, Olear E, Carpenter T, Deng Y, Chen C, Insogna KL.

Calcif Tissue Int. 2018 Jun;102(6):666-670. doi: 10.1007/s00223-017-0382-0. Epub 2018 Jan 30.

14.

Salmon calcitonin ameliorates migraine pain through modulation of CGRP release and dural mast cell degranulation in rats.

Kilinc E, Dagistan Y, Kukner A, Yilmaz B, Agus S, Soyler G, Tore F.

Clin Exp Pharmacol Physiol. 2018 Jun;45(6):536-546. doi: 10.1111/1440-1681.12915. Epub 2018 Feb 13.

PMID:
29344989
15.

A Drug Carrier for Sustained Zero-Order Release of Peptide Therapeutics.

Zhao YN, Xu X, Wen N, Song R, Meng Q, Guan Y, Cheng S, Cao D, Dong Y, Qie J, Liu K, Zhang Y.

Sci Rep. 2017 Jul 17;7(1):5524. doi: 10.1038/s41598-017-05898-6.

16.

Amylin receptor activation in the ventral tegmental area reduces motivated ingestive behavior.

Mietlicki-Baase EG, McGrath LE, Koch-Laskowski K, Krawczyk J, Reiner DJ, Pham T, Nguyen CTN, Turner CA, Olivos DR, Wimmer ME, Schmidt HD, Hayes MR.

Neuropharmacology. 2017 Sep 1;123:67-79. doi: 10.1016/j.neuropharm.2017.05.024. Epub 2017 May 25.

17.

Calcitonin gene-related peptide (CGRP): A novel target for Alzheimer's disease.

Singh Y, Gupta G, Shrivastava B, Dahiya R, Tiwari J, Ashwathanarayana M, Sharma RK, Agrawal M, Mishra A, Dua K.

CNS Neurosci Ther. 2017 Jun;23(6):457-461. doi: 10.1111/cns.12696. Epub 2017 Apr 17. Review.

18.

Supramolecular nanoparticles of calcitonin and dipeptide for long-term controlled release.

Cao S, Liu Y, Shang H, Li S, Jiang J, Zhu X, Zhang P, Wang X, Li J.

J Control Release. 2017 Jun 28;256:182-192. doi: 10.1016/j.jconrel.2017.04.014. Epub 2017 Apr 13.

PMID:
28414150
19.

The area postrema (AP) and the parabrachial nucleus (PBN) are important sites for salmon calcitonin (sCT) to decrease evoked phasic dopamine release in the nucleus accumbens (NAc).

Whiting L, McCutcheon JE, Boyle CN, Roitman MF, Lutz TA.

Physiol Behav. 2017 Jul 1;176:9-16. doi: 10.1016/j.physbeh.2017.03.023. Epub 2017 Mar 22.

20.

Amylin Acts in the Lateral Dorsal Tegmental Nucleus to Regulate Energy Balance Through Gamma-Aminobutyric Acid Signaling.

Reiner DJ, Mietlicki-Baase EG, Olivos DR, McGrath LE, Zimmer DJ, Koch-Laskowski K, Krawczyk J, Turner CA, Noble EE, Hahn JD, Schmidt HD, Kanoski SE, Hayes MR.

Biol Psychiatry. 2017 Dec 1;82(11):828-838. doi: 10.1016/j.biopsych.2016.12.028. Epub 2017 Jan 10.

Supplemental Content

Loading ...
Support Center